NCT04417348 - Opsin Receptors in Melasma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2019

Primary Completion Date

September 30, 2019

Study Completion Date

December 15, 2019

Conditions

Melasma

Interventions

DRUG

Retinoic acid

To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker

Trial Locations (1)

78290

"Dermatology Department. Hospital Central Dr. Ignacio Morones Prieto", San Luis Potosí City

All Listed Sponsors

collaborator

"Hospital Central Dr. Ignacio Morones Prieto"

OTHER

lead

Universidad Autonoma de San Luis Potosí

OTHER